Omar Alhalabi

1.9k total citations
102 papers, 604 citations indexed

About

Omar Alhalabi is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Omar Alhalabi has authored 102 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Surgery, 54 papers in Oncology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Omar Alhalabi's work include Bladder and Urothelial Cancer Treatments (52 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Urinary and Genital Oncology Studies (25 papers). Omar Alhalabi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (52 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Urinary and Genital Oncology Studies (25 papers). Omar Alhalabi collaborates with scholars based in United States, France and Syria. Omar Alhalabi's co-authors include Matthew T. Campbell, Vivek Subbiah, Isabella C. Glitza Oliva, Alvin H. Schmaier, Evi X. Stavrou, Jianjun Gao, Alona Merkulova, Amishi Y. Shah, Silvio Antoniak and Chao Fang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Omar Alhalabi

83 papers receiving 600 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Omar Alhalabi United States	12	242	191	161	115	73	102	604
Fadi Farhat Lebanon	17	196 0.8×	135 0.7×	234 1.5×	188 1.6×	48 0.7×	55	684
Jennifer Herring United States	11	347 1.4×	137 0.7×	175 1.1×	180 1.6×	81 1.1×	21	788
Michelle Afkhami United States	13	148 0.6×	74 0.4×	143 0.9×	135 1.2×	54 0.7×	58	579
Ping‐Tsung Chen Taiwan	14	201 0.8×	120 0.6×	126 0.8×	69 0.6×	30 0.4×	35	436
Rebecca S. Tidwell United States	11	351 1.5×	78 0.4×	199 1.2×	127 1.1×	46 0.6×	40	617
C. Bokemeyer Germany	16	268 1.1×	258 1.4×	299 1.9×	171 1.5×	53 0.7×	68	828
Alexis D. Leal United States	15	545 2.3×	163 0.9×	128 0.8×	244 2.1×	59 0.8×	57	888
May Cho United States	17	507 2.1×	178 0.9×	222 1.4×	156 1.4×	29 0.4×	57	834
Brieuc Sautois Belgium	13	188 0.8×	141 0.7×	171 1.1×	150 1.3×	130 1.8×	49	630
Joseph Sgouros Greece	14	347 1.4×	110 0.6×	118 0.7×	120 1.0×	33 0.5×	34	724

Countries citing papers authored by Omar Alhalabi

Since Specialization

Citations

This map shows the geographic impact of Omar Alhalabi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Alhalabi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Alhalabi more than expected).

Fields of papers citing papers by Omar Alhalabi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Alhalabi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Alhalabi. The network helps show where Omar Alhalabi may publish in the future.

Co-authorship network of co-authors of Omar Alhalabi

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Alhalabi. A scholar is included among the top collaborators of Omar Alhalabi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Alhalabi. Omar Alhalabi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hahn, Andrew W., Jad Chahoud, William Paul Skelton, et al.. (2025). LBA94 LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI). Annals of Oncology. 36. S1636–S1636.

Hahn, Andrew W., Jad Chahoud, William Paul Skelton, et al.. (2025). A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). Annals of Oncology. 37(2). 241–249.

Raggi, Daniele, Filippo Pederzoli, Alberto Martini, et al.. (2025). HER2 and urothelial carcinoma: current understanding and future directions. Nature Reviews Urology. 23(2). 110–132. 1 indexed citations

Adesoye, Taiwo, Ecaterina E. Dumbrava, Kanwal Raghav, et al.. (2025). Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. Clinical Cancer Research. 32(2). 260–290.

Jiang, C.-Y., Omar Alhalabi, Edwin C. Oh, et al.. (2025). 3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study. Annals of Oncology. 36. S1489–S1489.

Fang, Andrew M., Hyunsoo Hwang, Nathaniel R. Wilson, et al.. (2024). Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. ESMO Open. 9(11). 103964–103964. 2 indexed citations

Campbell, Matthew T., et al.. (2024). Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?. Biomedicines. 12(3). 519–519. 12 indexed citations

Wilson, Nathaniel R., Lianchun Xiao, Jianjun Gao, et al.. (2024). Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO).. Journal of Clinical Oncology. 42(16_suppl). 4605–4605. 1 indexed citations

Cho, Woo Cheal, Priyadharsini Nagarajan, Phyu P. Aung, et al.. (2024). Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of Cutaneous Pathology. 51(5). 360–367. 6 indexed citations

10.

Alhalabi, Omar, Dimitra Rafailia Bakaloudi, Amanda Nizam, et al.. (2024). Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.. Journal of Clinical Oncology. 42(4_suppl). 651–651. 1 indexed citations

11.

Ratliff, Hunter N., Malek Shatila, Muhammad Ali Khan, et al.. (2023). The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review. Journal of Cancer. 14(16). 2956–2963. 10 indexed citations

12.

Hahn, Andrew W., Devaki Shilpa Surasi, Tharakeswara Bathala, et al.. (2023). Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. The Oncologist. 29(5). 392–399. 4 indexed citations

13.

Alhalabi, Omar, Sylvie Négrier, Yann Vano, et al.. (2023). Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The Oncologist. 28(5). 433–439. 13 indexed citations

14.

Dondossola, Eleonora, Nathaniel R. Wilson, Omar Alhalabi, et al.. (2023). Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology. 164(6). 5 indexed citations

15.

Wang, Jianbo, Matthew T. Campbell, Amishi Y. Shah, et al.. (2023). A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.. Journal of Clinical Oncology. 41(6_suppl). TPS745–TPS745. 1 indexed citations

16.

Alhalabi, Omar, Rahul A. Sheth, Amishi Y. Shah, et al.. (2023). 660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC). SHILAP Revista de lepidopterología. A752–A752. 1 indexed citations

17.

Hensley, Patrick J., Kelly K. Bree, Matthew T. Campbell, et al.. (2021). Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. The Journal of Urology. 206(5). 1258–1267. 12 indexed citations

18.

Alhalabi, Omar, Ryan Sun, Elshad Hasanov, et al.. (2021). Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. npj Breast Cancer. 7(1). 28–28. 5 indexed citations

19.

Hahn, Andrew W., Omar Alhalabi, Pavlos Msaouel, et al.. (2020). Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 5(6). e001073–e001073. 3 indexed citations

20.

Yadav, Siddhartha, et al.. (2017). Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. Clinical Breast Cancer. 18(5). e1229–e1235. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact